Intrahepatic cholangiocarcinoma treated with local-regional therapy: Quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response

Vivek Gowdra Halappa, Susanne Bonekamp, Celia Corona Villalobos, Zhen Li, Margaret Mensa, Diane Reyes, John Eng, Nikhil Bhagat, Timothy M. Pawlik, Jean François Geschwind, Ihab R Kamel

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate volumetric changes in apparent diffusion coefficient (ADC) and contrast material enhancement on contrast-enhanced (CE) magnetic resonance (MR) images in hepatic arterial and portal venous phases for assessing early response in cholangiocarcinoma treated with transcatheter arterial chemoembolization (TACE). Materials and Methods: Twenty-nine patients with unresectable cholangiocarcinoma, including 11 men (mean age, 60 years; standard deviation, 16.8) and 18 women (mean age, 63 years; standard deviation, 11.5) were included in this retrospective institutional review board-approved, HIPAA-compliant study; informed consent was waived. Sixty-nine TACE procedures were performed during the observational time (range, one to five TACE sessions). No patients received another form of therapy after treatment with TACE. MR Imaging was performed before and 3-4 weeks after TACE, and images were analyzed with a semiautomatic volumetric software package. Patients were stratified as responders and nonresponders on the basis of overall survival (OS) as the primary end point. Differences between responders and nonresponders were analyzed with paired t tests, and OS was calculated with the Kaplan-Meier method. Significant differences were analyzed with the log-rank test. Results: Mean volumetric ADC increased from 1.54 × 10-3 mm2/ sec to 1.92 × 10-3 mm2/sec (P <.0001), with no significant decrease in mean volumetric enhancement in hepatic arterial (40.6% vs 37.5%, P = .546) and portal venous (79.0% vs 70.0%, P = .105) phases. Patients who demonstrated improved survival of 10 months or more had a significant increase in mean volumetric ADC and volumetric ADC above the threshold level of 1.60 × 10-3 mm2/ sec (P <.002). Patients with 45% or greater (n = 21; logrank test, P <.02) and 60% or greater (n = 12; log-rank test, P <.009) ADC changes for the whole tumor volume demonstrated better OS compared with patients in whom these ADC changes were not achieved. Conclusion: Patients with percentage tumor volume increase in ADC of 45% or greater and 60% or greater above the threshold level of 1.60 × 10-3 mm2/sec had favorable response to therapy and improved survival.

Original languageEnglish (US)
Pages (from-to)285-294
Number of pages10
JournalRadiology
Volume264
Issue number1
DOIs
StatePublished - Jul 2012

Fingerprint

Cholangiocarcinoma
Survival
Neoplasms
Tumor Burden
Therapeutics
Health Insurance Portability and Accountability Act
Research Ethics Committees
Liver
Informed Consent
Contrast Media
Magnetic Resonance Spectroscopy
Software
Magnetic Resonance Imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Intrahepatic cholangiocarcinoma treated with local-regional therapy : Quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. / Halappa, Vivek Gowdra; Bonekamp, Susanne; Corona Villalobos, Celia; Li, Zhen; Mensa, Margaret; Reyes, Diane; Eng, John; Bhagat, Nikhil; Pawlik, Timothy M.; Geschwind, Jean François; Kamel, Ihab R.

In: Radiology, Vol. 264, No. 1, 07.2012, p. 285-294.

Research output: Contribution to journalArticle

Halappa, Vivek Gowdra ; Bonekamp, Susanne ; Corona Villalobos, Celia ; Li, Zhen ; Mensa, Margaret ; Reyes, Diane ; Eng, John ; Bhagat, Nikhil ; Pawlik, Timothy M. ; Geschwind, Jean François ; Kamel, Ihab R. / Intrahepatic cholangiocarcinoma treated with local-regional therapy : Quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. In: Radiology. 2012 ; Vol. 264, No. 1. pp. 285-294.
@article{bd90113ad8cb4409ad2014caf7a8da70,
title = "Intrahepatic cholangiocarcinoma treated with local-regional therapy: Quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response",
abstract = "Purpose: To evaluate volumetric changes in apparent diffusion coefficient (ADC) and contrast material enhancement on contrast-enhanced (CE) magnetic resonance (MR) images in hepatic arterial and portal venous phases for assessing early response in cholangiocarcinoma treated with transcatheter arterial chemoembolization (TACE). Materials and Methods: Twenty-nine patients with unresectable cholangiocarcinoma, including 11 men (mean age, 60 years; standard deviation, 16.8) and 18 women (mean age, 63 years; standard deviation, 11.5) were included in this retrospective institutional review board-approved, HIPAA-compliant study; informed consent was waived. Sixty-nine TACE procedures were performed during the observational time (range, one to five TACE sessions). No patients received another form of therapy after treatment with TACE. MR Imaging was performed before and 3-4 weeks after TACE, and images were analyzed with a semiautomatic volumetric software package. Patients were stratified as responders and nonresponders on the basis of overall survival (OS) as the primary end point. Differences between responders and nonresponders were analyzed with paired t tests, and OS was calculated with the Kaplan-Meier method. Significant differences were analyzed with the log-rank test. Results: Mean volumetric ADC increased from 1.54 × 10-3 mm2/ sec to 1.92 × 10-3 mm2/sec (P <.0001), with no significant decrease in mean volumetric enhancement in hepatic arterial (40.6{\%} vs 37.5{\%}, P = .546) and portal venous (79.0{\%} vs 70.0{\%}, P = .105) phases. Patients who demonstrated improved survival of 10 months or more had a significant increase in mean volumetric ADC and volumetric ADC above the threshold level of 1.60 × 10-3 mm2/ sec (P <.002). Patients with 45{\%} or greater (n = 21; logrank test, P <.02) and 60{\%} or greater (n = 12; log-rank test, P <.009) ADC changes for the whole tumor volume demonstrated better OS compared with patients in whom these ADC changes were not achieved. Conclusion: Patients with percentage tumor volume increase in ADC of 45{\%} or greater and 60{\%} or greater above the threshold level of 1.60 × 10-3 mm2/sec had favorable response to therapy and improved survival.",
author = "Halappa, {Vivek Gowdra} and Susanne Bonekamp and {Corona Villalobos}, Celia and Zhen Li and Margaret Mensa and Diane Reyes and John Eng and Nikhil Bhagat and Pawlik, {Timothy M.} and Geschwind, {Jean Fran{\cc}ois} and Kamel, {Ihab R}",
year = "2012",
month = "7",
doi = "10.1148/radiol.12112142",
language = "English (US)",
volume = "264",
pages = "285--294",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Intrahepatic cholangiocarcinoma treated with local-regional therapy

T2 - Quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response

AU - Halappa, Vivek Gowdra

AU - Bonekamp, Susanne

AU - Corona Villalobos, Celia

AU - Li, Zhen

AU - Mensa, Margaret

AU - Reyes, Diane

AU - Eng, John

AU - Bhagat, Nikhil

AU - Pawlik, Timothy M.

AU - Geschwind, Jean François

AU - Kamel, Ihab R

PY - 2012/7

Y1 - 2012/7

N2 - Purpose: To evaluate volumetric changes in apparent diffusion coefficient (ADC) and contrast material enhancement on contrast-enhanced (CE) magnetic resonance (MR) images in hepatic arterial and portal venous phases for assessing early response in cholangiocarcinoma treated with transcatheter arterial chemoembolization (TACE). Materials and Methods: Twenty-nine patients with unresectable cholangiocarcinoma, including 11 men (mean age, 60 years; standard deviation, 16.8) and 18 women (mean age, 63 years; standard deviation, 11.5) were included in this retrospective institutional review board-approved, HIPAA-compliant study; informed consent was waived. Sixty-nine TACE procedures were performed during the observational time (range, one to five TACE sessions). No patients received another form of therapy after treatment with TACE. MR Imaging was performed before and 3-4 weeks after TACE, and images were analyzed with a semiautomatic volumetric software package. Patients were stratified as responders and nonresponders on the basis of overall survival (OS) as the primary end point. Differences between responders and nonresponders were analyzed with paired t tests, and OS was calculated with the Kaplan-Meier method. Significant differences were analyzed with the log-rank test. Results: Mean volumetric ADC increased from 1.54 × 10-3 mm2/ sec to 1.92 × 10-3 mm2/sec (P <.0001), with no significant decrease in mean volumetric enhancement in hepatic arterial (40.6% vs 37.5%, P = .546) and portal venous (79.0% vs 70.0%, P = .105) phases. Patients who demonstrated improved survival of 10 months or more had a significant increase in mean volumetric ADC and volumetric ADC above the threshold level of 1.60 × 10-3 mm2/ sec (P <.002). Patients with 45% or greater (n = 21; logrank test, P <.02) and 60% or greater (n = 12; log-rank test, P <.009) ADC changes for the whole tumor volume demonstrated better OS compared with patients in whom these ADC changes were not achieved. Conclusion: Patients with percentage tumor volume increase in ADC of 45% or greater and 60% or greater above the threshold level of 1.60 × 10-3 mm2/sec had favorable response to therapy and improved survival.

AB - Purpose: To evaluate volumetric changes in apparent diffusion coefficient (ADC) and contrast material enhancement on contrast-enhanced (CE) magnetic resonance (MR) images in hepatic arterial and portal venous phases for assessing early response in cholangiocarcinoma treated with transcatheter arterial chemoembolization (TACE). Materials and Methods: Twenty-nine patients with unresectable cholangiocarcinoma, including 11 men (mean age, 60 years; standard deviation, 16.8) and 18 women (mean age, 63 years; standard deviation, 11.5) were included in this retrospective institutional review board-approved, HIPAA-compliant study; informed consent was waived. Sixty-nine TACE procedures were performed during the observational time (range, one to five TACE sessions). No patients received another form of therapy after treatment with TACE. MR Imaging was performed before and 3-4 weeks after TACE, and images were analyzed with a semiautomatic volumetric software package. Patients were stratified as responders and nonresponders on the basis of overall survival (OS) as the primary end point. Differences between responders and nonresponders were analyzed with paired t tests, and OS was calculated with the Kaplan-Meier method. Significant differences were analyzed with the log-rank test. Results: Mean volumetric ADC increased from 1.54 × 10-3 mm2/ sec to 1.92 × 10-3 mm2/sec (P <.0001), with no significant decrease in mean volumetric enhancement in hepatic arterial (40.6% vs 37.5%, P = .546) and portal venous (79.0% vs 70.0%, P = .105) phases. Patients who demonstrated improved survival of 10 months or more had a significant increase in mean volumetric ADC and volumetric ADC above the threshold level of 1.60 × 10-3 mm2/ sec (P <.002). Patients with 45% or greater (n = 21; logrank test, P <.02) and 60% or greater (n = 12; log-rank test, P <.009) ADC changes for the whole tumor volume demonstrated better OS compared with patients in whom these ADC changes were not achieved. Conclusion: Patients with percentage tumor volume increase in ADC of 45% or greater and 60% or greater above the threshold level of 1.60 × 10-3 mm2/sec had favorable response to therapy and improved survival.

UR - http://www.scopus.com/inward/record.url?scp=84862657180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862657180&partnerID=8YFLogxK

U2 - 10.1148/radiol.12112142

DO - 10.1148/radiol.12112142

M3 - Article

C2 - 22627601

AN - SCOPUS:84862657180

VL - 264

SP - 285

EP - 294

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 1

ER -